SECOND AGREEMENT REGARDING PRIVATE PLACEMENT OF SECURITIES OF SUNESIS PHARMACEUTICALS, INC.
Exhibit 10.66
SECOND AGREEMENT REGARDING PRIVATE PLACEMENT OF SECURITIES
OF
SUNESIS PHARMACEUTICALS, INC.
THIS AGREEMENT (the “Agreement”) is made and entered into as of this 27th day of October, 2009, by and among SUNESIS PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and the persons and entities listed on Exhibit A hereto (the “Investors”).
RECITALS
A. The Company and the Investors wish to amend that certain Securities Purchase Agreement, dated March 31, 2009, as amended on June 29, 2009 (as amended, the “Purchase Agreement”), by and among the Company and the Purchasers (as defined in the Purchase Agreement) and that certain Investor Rights Agreement, dated April 3, 2009, as amended June 29, 2009 (as amended, the “Rights Agreement”), by and among the Company and the Investors (as defined in the Rights Agreement);
B. The Majority Purchasers (as defined in the Purchase Agreement) delivered the Purchaser Second Unit Closing Notice (as defined in the Purchase Agreement) on October 20, 2009;
C. Pursuant to Section 7.4 of the Purchase Agreement, the Purchase Agreement may be amended only by a written instrument signed by the Company and the Purchaser or Purchasers holding or having the right to acquire, at the time of such amendment, at least a majority-in-interest of the total Unit Shares (as defined in the Purchase Agreement);
D. Pursuant to Section 8(c) of the Rights Agreement, Section 7(b) of the Rights Agreement may be amended only by written consent of the Company, the Majority Investors (as defined in the Rights Agreement) and Alta Partners, Bay City Capital, NEA and Nextech (each as defined in the Rights Agreement); and
E. The undersigned hold or have the right to acquire at least a majority-in-interest of the total Unit Shares and constitute the Majority Investors and include Alta Partners, Bay City Capital, NEA and Nextech (collectively, the “Requisite Investors”).
AGREEMENT
NOW, THEREFORE, in consideration of these premises and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:
1. AMENDMENT TO PURCHASE AGREEMENT. All capitalized terms not otherwise defined in this Section 1 shall be as defined in the Purchase Agreement.
(a) The Company and the undersigned hereby agree that the definition of “Common Equity Closing Date” in Section 1.1 of the Purchase Agreement is hereby amended and restated to read as follows:
“‘Common Equity Closing Date’ means the first (1st) Trading Day after the date on which the last to be satisfied or waived of the applicable conditions set forth in Sections 2.1(a)(iii), 2.2(c)-(e), 5.5 and 5.6, except for those conditions and deliveries that are to be made at the Common Equity Closing; provided, however, that the Common
1.
Equity Closing Date shall not occur prior to (i) the earlier of (X) the fifteenth (15th) tenth (10th) Trading Day after the date on which the Majority Purchasers would have been required to have delivered a Non-Participation Notice pursuant to Section 2.1(a)(iii) of this Agreement in order for the Purchasers to be not required to
participate in the Common Equity Closing and (Y) the fifteenth (15th) tenth (10th) Trading Day after the date on which the Lead
Purchasers deliver a Purchaser Put Notice pursuant to Section 2.1(a)(iii) of this Agreement, or (ii) the consummation of the Second Unit Closing if the Purchasers have previously delivered the Purchaser Second Unit Closing Notice
(including delivery of such notice after delivery by the Company of the Company Election Notice and prior to the consummation of the Common Equity Closing).”
(b) The Company and the undersigned hereby agree that the definition of “Purchaser Put Notice” in Section 1.1 of the Purchase Agreement is hereby amended and restated to read as follows:
“‘Purchaser Put
Notice’ means a written notice by the Lead Purchasers to the Company and all Purchasers, which shall be delivered if the Majority Purchasers elect to consummate the Common Equity Closing and shall set forth such election, delivered
(i) at any time prior to January 8, 2010, (ii) on or before January 15, 2010, if a Cash Balance Notice is delivered no later than January 12, 2010 and such Cash Balance Notice reflects a Cash balance of less than
$4.0 million $2.5 million as of January 8, 2010 or (iii) if a Cash Balance Notice delivered no later than January 12, 2010 sets forth the Company’s Cash balance as greater than $4.0
million $2.5 million as of January 8, 2010, at any time prior to the earlier of (A) December 31, 2010, (B) five (5) Trading Days following the delivery to the Lead Purchasers of a Cash Balance Notice
reflecting a Cash balance of the Company of less than $4.0 million $2.5 million and (C) the closing of an Alternative Common Stock Financing.”
(c) The Company and the undersigned hereby agree that the definition of “Second Unit Closing Date” in Section 1.1 of the Purchase Agreement is hereby amended and restated to read as follows:
“‘Second Unit Closing Date’ means the first (1st) Trading Day after the date on which the last to be satisfied or waived of the conditions set forth in Sections 2.1(a)(ii), 2.2(b), (d) and (e), 5.3 and 5.4 shall have been satisfied or waived,
except for those conditions and deliveries that are to be made at the Second Unit Closing; provided, however, that the Second Unit Closing Date shall not occur prior to the fifteenth (15th) Trading Day after the date on which a Company Second Unit Closing Notice, Purchaser Second Unit
Closing Notice or Majority Purchaser Second Unit Closing Notice, as applicable, is validly delivered pursuant to this Agreement.”
The Company and the undersigned acknowledge that the Second Unit Closing Date is targeted to be October 30, 2009, subject to the satisfaction or waiver of the deliveries and conditions set forth in Sections 2.1(a)(ii), 2.2(b), (d) and (e), 5.3 and 5.4.
(d) The Company and the undersigned hereby agree that a new Section 4.15 is hereby added to the Purchase Agreement to read as follows:
“4.15 Cash Balance. The Company shall deliver to the Lead Purchasers a Cash Balance Notice no later than January 12, 2010 that sets forth the Company’s Cash balance as of January 8, 2010. The Company will use commercially reasonable efforts to cause the Company to maintain a Cash balance of at least $2.5 million as of January 8, 2010 and will
2.
not take any action intended to have the effect of causing the Cash balance to fall below $2.5 million as of such date; provided, however, that, nothing in this Section 4.15 shall prevent the Company from paying accounts payable and taking other actions in the ordinary course of business consistent with past practice and the Company’s Board-approved operating plan.”
2. AMENDMENT TO RIGHTS AGREEMENT. All capitalized terms not otherwise defined in this Section 2 shall be as defined in the Rights Agreement. The Company and the undersigned hereby agree that Section 7(b)(2) of the Rights Agreement is hereby amended and restated to read as follows:
“Subject to Section 7(b)(6) below, from and after the earlier to occur of (i) the Second Unit Closing, (ii) the Common Equity Closing and (iii) the closing of an Alternative Common Stock Financing in which the Investors exercise preemptive rights pursuant to the terms of this Agreement and, as a result, beneficially own greater than a majority of the Company’s voting stock as of such closing, the Company shall take all appropriate action to promptly establish and maintain the size of the Board at nine (9) members, five (5) of which shall be Investor Designees and nominated in accordance with the provisions of this Section 7(b). Alta Partners, Bay City Capital, NEA and Nextech, together with their respective affiliates, shall each have the right to designate one (1) such Investor Designee. Notwithstanding the foregoing, the Company’s obligation to set and maintain the size of the Board at nine (9) members and the Investors’ right to designate five (5) Investor Designees pursuant to this Section 7(b)(2) shall not be effective prior to January 1, 2010 or such later date as determined by the Majority Investors. On or prior to January 20 of each year in which the Majority Investors have rights pursuant to this Section 7(b) (assuming the Company has made a request therefor at least five (5) Trading Days prior thereto), and within five (5) Trading Days of the request by the Company in connection with the preparation of a proxy statement with respect to the election of members of the Board or a vacancy created on the Board by the resignation, death or disability of an Investor Designee or the failure of an Investor Designee to be elected at a meeting of the Company at any time at which the Majority Investors have rights pursuant to this Section 7(b), each Investor shall notify the Company of the number of voting shares of the Company’s capital stock beneficially owned by such Investor as of a date within five (5) Trading Days of the delivery of such notice.”
3. MISCELLANEOUS. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. A facsimile, telecopy or other reproduction of this Agreement may be executed by one or more parties hereto and delivered by such party by facsimile or any similar electronic transmission device pursuant to which the signature of or on behalf of such party can be seen. Such execution and delivery shall be considered valid, binding and effective for all purposes. At the request of any party hereto, all parties hereto agree to execute and deliver an original of this Agreement as well as any facsimile, telecopy or other reproduction hereof. Other than as set forth herein, the Purchase Agreement and the Rights Agreement shall remain in full force and effect. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of California, without regard to the principles of conflicts of law thereof. Upon the execution of this Agreement by the Company and the Requisite Investors, all parties to the Purchase Agreement and the Rights Agreement shall be bound by this Agreement.
[SIGNATURE PAGE TO FOLLOW]
3.
IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above written.
| COMPANY: | INVESTORS: | |||||||
| SUNESIS PHARMACEUTICALS, INC. | BAY CITY CAPITAL FUND V, L.P. | |||||||
| Signature: | /s/ Xxxxxx X. Xxxxxxx, Xx. |
By: | /s/ Xxxx Xxxxxxxxxxx | |||||
| Print Name: | Xxxxxx X. Xxxxxxx, Xx. | Name: | Xxxx Xxxxxxxxxxx | |||||
| Title: | President and CEO | Title: | Manager and Managing Director | |||||
| Address: | 000 Xxxxxx Xxxxx Xxxxxxxxx, #000 | |||||||
| Xxxxx Xxx Xxxxxxxxx, XX 00000 | ||||||||
| BAY CITY CAPITAL FUND V CO-INVESTMENT FUND, L.P. | ||||||||
| By: | /s/ Xxxx Xxxxxxxxxxx | |||||||
| Name: | Xxxx Xxxxxxxxxxx | |||||||
| Title: | Manager and Managing Director | |||||||
| GROWTH EQUITY OPPORTUNITIES FUND, LLC | ||
| By: | /s/ Xxxxxxx X. Xxxxxxx III | |
| Name: | Xxxxxxx X. Xxxxxxx III | |
| Title: | Manager of NEA 12 GP, LLC, the sole general partner of NEA Partners 12, Limited Partnership, the sole general partner of New Enterprise Associates 12, Limited Partnership, the sole member of Growth Equity Opportunities Fund, LLC | |
| ALTA BIOPHARMA PARTNERS III, L.P. | ||
| By: | /s/ Xxxxxx Xxxxxx | |
| Name: | Xxxxxx Xxxxxx | |
| Title: | VP of Finance and Admin. | |
| ALTA BIOPHARMA PARTNERS III GMBH & CO. BETEILIGUNGS KG | ||
| By: | /s/ Xxxxxx Xxxxxx | |
| Name: | Xxxxxx Xxxxxx | |
| Title: | VP of Finance and Admin. | |
| ALTA EMBARCADERO BIOPHARMA PARTNERS III, LLC | ||
| By: | /s/ Xxxxxx Xxxxxx | |
| Name: | Xxxxxx Xxxxxx | |
| Title: | VP of Finance and Admin. | |
| MERLIN NEXUS III, L.P. | ||
| By: | /s/ Xxxxxxxxx Xxxxx | |
| Name: | Xxxxxxxxx Xxxxx | |
| Title: | Managing Partner | |
| NEXUS GEMINI, L.P. | ||
| By: | /s/ Xxxxxxxxx Xxxxx | |
| Name: | Xxxxxxxxx Xxxxx | |
| Title: | Managing Partner | |
| ONC GENERAL PARTNER LIMITED AS GENERAL PARTNER OF ONC PARTNERS, L.P. | ||
| By: | /s/ Xxxxxx Xxxx | |
| Name: | Xxxxxx Xxxx | |
| Title: | Director | |
| VISION OPPORTUNITY MASTER FUND, LTD. | ||
| By: | /s/ Xxxx Xxxxxxxx | |
| Name: | Xxxx Xxxxxxxx | |
| Title: | Director | |
| CAXTON ADVANTAGE LIFE SCIENCES FUND, L.P. | ||
| By: | /s/ Xxxx X. Xxxxxxx | |
| Name: | Xxxx X. Xxxxxxx | |
| Title: | Managing Director | |
| VENROCK ASSOCIATES | ||
| By: | /s/ Xxxxxxx X. Xxxxx | |
| Name: | Xxxxxxx X. Xxxxx | |
| Title: | General Partner | |
| VENROCK ASSOCIATES II, L.P. | ||
| By: | /s/ Xxxxxxx X. Xxxxx | |
| Name: | Xxxxxxx X. Xxxxx | |
| Title: | General Partner | |
| OPUS POINT HEALTHCARE (LOW NET) FUND, L.P. | ||
| By: | /s/ Xxxxxxx X. Xxxxx | |
| Name: | Xxxxxxx X. Xxxxx | |
| Title: | Manager of the Investment Manager | |
| OPUS POINT HEALTHCARE VALUE FUND, L.P. | ||
| By: | /s/ Xxxxxxx X. Xxxxx | |
| Name: | Xxxxxxx X. Xxxxx | |
| Title: | Manager of the Investment Manager | |
| XXXXXXX REVOCABLE TRUST | ||
| By: | /s/ Xxxxxx X. Xxxxxxx, Xx. | |
| Name: | Xxxxxx X. Xxxxxxx, Xx. | |
| Title: | Trustee | |
| BJERKHOLT/XXXX FAMILY TRUST | ||
| By: | /s/ Xxxx Xxxxxxxxx | |
| Name: | Xxxx Xxxxxxxxx | |
| Title: | ||
| XXXXXX XXXXX XXXXXXX | ||
| By: | /s/ Xxxxxx Xxxxx Xxxxxxx | |
EXHIBIT A
LIST OF INVESTORS
Bay City Capital Fund V, L.P.
Bay City Capital Fund V Co-Investment Fund, L.P.
Growth Equity Opportunities Fund, LLC
Alta BioPharma Partners III, L.P.
Alta BioPharma Partners III GmbH & Co. Beteiligungs KG
Alta Embarcadero BioPharma Partners III, LLC
Merlin Nexus III, L.P.
Nexus Gemini, L.P.
ONC General Partner Limited as General Partner of ONC Partners, L.P.
Vision Opportunity Master Fund, Ltd.
Caxton Advantage Life Sciences Fund, L.P.
Venrock Associates
Venrock Associates II, L.P.
Opus Point Healthcare (Low Net) Fund, L.P.
Opus Point Healthcare Value Fund, X.X.
Xxxxxxx Revocable Trust
Bjerkholt/Xxxx Family Trust
Xxxxxx Xxxxx Xxxxxxx
